Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.84 USD | -9.11% | -10.29% | +11.32% |
04-16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
04-11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.32% | 717M | |
+3.68% | 108B | |
+11.04% | 104B | |
+1.28% | 22.33B | |
-12.87% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.25% | 17.64B | |
+3.69% | 14.05B | |
+37.29% | 12.51B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- Raymond James Raises Price Target on AnaptysBio to $38 From $30, Maintains Outperform Rating